Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience

被引：0
|
作者：
Ahmadi-Simab, K
Lamprecht, P
Hellmisch, B
Gross, WL
机构：
[1] Univ Klinikum Schleswig Holstein, Poliklin Rheumatol, D-23538 Lubeck, Germany
[2] Rheumaklin Bad Bramstedt, D-23538 Lubeck, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2004年 / 63卷 / 06期
关键词：
D O I：
10.1007/s00393-004-0594-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：495 / 497
页数：3
相关论文
共 50 条
  • [21] Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases
    Marc Humbert
    Gérald Simonneau
    Nature Clinical Practice Rheumatology, 2005, 1 : 93 - 101
  • [22] Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases
    Humbert, M
    Simonneau, G
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2005, 1 (02): : 93 - 101
  • [23] Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
    Channick, RN
    Simonneau, G
    Sitbon, O
    Robbins, IM
    Frost, A
    Tapson, VF
    Badesch, DB
    Roux, S
    Rainisio, M
    Bodin, F
    Rubin, LJ
    LANCET, 2001, 358 (9288): : 1119 - 1123
  • [24] Improved survival of systemic sclerosis-associated pulmonary arterial hypertension (SSC-PAH) in the endothelin antagonist era
    Williams, MH
    Das, C
    Handler, CE
    Akram, MR
    Davar, J
    Denton, CP
    Smith, CJ
    Black, CM
    Coghlan, JG
    HEART, 2005, 91 : A64 - A65
  • [25] Long term treatment with bosentan for pulmonary arterial hypertension related to systemic sclerosis
    Cozzi, F
    Montisci, R
    Marotta, H
    Bobbo, F
    Favaro, M
    Tiso, F
    Ciprian, L
    Iliceto, S
    Todesco, S
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 297 - 297
  • [26] Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension
    Suleman, N
    Frost, AE
    CHEST, 2004, 126 (03) : 808 - 815
  • [27] Tracleer (bosentan), a dual endothelin receptor antagonist (ERA), for the treatment of pulmonary arterial hypertension (PAH) related to connective tissue diseases: Effect on quality of life (QoL)
    Proudman, S
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S692 - S692
  • [28] Protective effect of Bosentan on vascular endothelium in patients with pulmonary arterial hypertension (PAH) related to systemic sclerosis
    Del Papa, N
    Cortiana, M
    Comina, DP
    Maglione, W
    Manara, M
    Vitali, C
    Fracchiolla, N
    Cortelezzi, A
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 299 - 299
  • [29] After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension
    Tamargo, Juan
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (05) : 371 - 373
  • [30] Ambrisentan -: Treatment of pulmonary arterial hypertension endothelin ETA receptor antagonist
    Sorbera, LA
    Castañer, J
    DRUGS OF THE FUTURE, 2005, 30 (08) : 765 - 770
12345